Samarium lexidronam (153Sm-EDTMP): Skeletal radiation for osteoblastic bone metastases and osteosarcoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1517-1527

  Anderson, Pete ^a   Nuñez, Rodolfo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

153Sm EDTMP; Bone cancer; Bone pain; Bone scan; Breast cancer chemotherapy; External beam radiotherapy; Lesion irradiation; Leukemia; Marrow radiation; Metastatic cancer; Myeloma; Osteoblastic osseous metastases; Osteosarcoma; Prostate cancer; Radiation; Radiosensitization; Samarium; Scintigraphy; Skeletal metastases

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; GEMCITABINE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; METHOTREXATE; NITROSOUREA; OXALIPLATIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; THALIDOMIDE; ZOLEDRONIC ACID; ANALGESIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHEMISTRY; CLINICAL TRIAL; CYTOPENIA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; EXTERNAL BEAM RADIOTHERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOCALCEMIA; INFERTILITY; INJECTION SITE REACTION; LEUKEMIA; LIVER DISEASE; LUNG DISEASE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PHARMACODYNAMICS; PROSTATE CARCINOMA; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; ANIMAL; BONE TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANALGESICS, NON-NARCOTIC; ANIMALS; BONE NEOPLASMS; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; OSTEOSARCOMA; RADIOISOTOPES; SAMARIUM;

EID: 37349120734     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1517     Document Type: Article

References (93)

1. Janjan N. Bone metastases: approaches to management. Semin. Oncol. 28, 28-34 (2001).
2. Janjan N. Palliation and supportive care in radiation medicine. Hematol. Oncol. Clin. North Am. 20, 187-211 (2006).
3. Samant R, Gooi AC. Radiotherapy basics for family physicians. Potent tool for symptom relief. Can. Fam. Physician 51, 1496-1501 (2005).
4. Reisfield GM, Silberstein EB, Wilson GR. Radiopharmaceuticals for the palliation of painful bone metastases. Am. J. Hosp. Palliat. Care 22, 41-46 (2005).
5. Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin. Pharmacother. 7, 1475-1486 (2006).
6. Agarawal JP, Swangsilpa T, van der Linden Y et al. The role of external beam radiotherapy in the management of bone metastases. Clin. Oncol. (R. Coll. Radiol.) 18, 747-760 (2006).
7. Hillegonds DJ, Franklin S, Shelton DK et al. The management of painful bone metastases with an emphasis on radionuclide therapy. J. Natl. Med. Assoc. 99, 785-794 (2007).
8. Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med. Chem. 7, 381-397 (2007).
9. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev. 25, 669-675 (2006).
10. 18F-fluoride on osteoblasts. Eur. J. Nucl. Med. Mol. Imaging 33, 491-494 (2006).
11. 153Sm radiotherapeutic bone agents. Int. J. Rad. Appl. Instrum. [B] 13, 479-482 (1986).
12. Atkins HL, Srivastava SC. Radiolabeled bone-seeking radiopharmaceuticals. Q. J. Nucl. Med. 40, 285-289 (1996).
13. Goeckeler WF, Edwards B, Volkert WA et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 28, 495-504 (1987).
14. 153Sm for radionuclide therapy. Nucl. Med. Commun. 23, 83-89 (2002).
15. 154Eu, a new reference source for calibration in γ-ray spectrometry. Appl. Radiat. Isot. 62, 17-23 (2005).
16. Coursey BM, Hoppes DD, Schima FJ, Unterweger MP. The standardization of samarium-153. Int. J. Rad. Appl. Instrum. [A] 38, 31-34 (1987).
17. Quadramete®. In: Physician's Desk Reference Product Information (61st Edition). Thompson PDR, NJ, USA 1040-1042 (2007).
18. van Rensburg AJ, Alberts AS, Louw WK. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J. Nucl. Med. 39, 2110-2115 (1998).
19. 153Sm-EDTMP. Nucl. Med. Biol. 20, 657-661 (1993).
20. Anderson PM, Wiseman GA, Dispenzieri A et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin. Oncol. 20, 189-196 (2002).
21. Louw WK, Dormehl IC, van Rensburg AJ et al. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol. 23, 935-940 (1996).
22. Bayouth JE, Macey DJ. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med. Phys. 20, 1089-1096 (1993).
23. 153Sm lexidronam. Drug Aging 11, 413-419 (1997).
24. Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res. 11, 6895-6900 (2005).
25. 153Sm-ethylenediaminetetramethylene-phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer 33, 1583-1591 (1997).
26. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63, 940-945 (2004).
27. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 16, 1574-1581 (1998).
28. Bruland OS, Skretting A, Solheim OP, Aas M. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol. 35, 381-384 (1996).
29. Mahajan A, Anderson PM, Hughes D et al. Multimodality local management of recurent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatr. Blood Cancer (2007) (In Press).
30. Mahajan A, Woo S, Kotnguth D et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr. Blood Cancer (2008) (In Press).
31. Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. 20, 1953-1954 (2002).
32. Franzius C, Bielack S, Flege S et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nukleamedizin 40, 215-220 (2001).
33. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl. 2), S150-S162 (2007).
34. Perez EA. Metastatic bone disease in breast cancer: the patient's perspective. Semin. Oncol. 28, 60-63 (2001).
35. Coleman RE. Bisphosphonates in breast cancer. Ann. Oncol. 16, 687-695 (2005).
36. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. 29, 321-327 (2003).
37. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. 16, 2038-2044 (1998).
38. Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol. 46, 581-591 (2007).
39. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J. Pain Symptom Manage. 33, 462-472 (2007).
40. Diel IJ. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15(11), 1243-1249 (2007) (Epub ahead of print).
41. Santini D, Fratto ME, Vincenzi B et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin. Biol. Ther. 6, 1333-1348 (2006).
42. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 96, 964-969 (2005).
43. Marcus CS, Saeed S, Mlikotic A et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin. Nucl. Med. 27, 427-430 (2002).
44. Wang RF, Zhang CL, Zhu SL, Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med. Princ. Pract. 12, 97-101 (2003).
45. 153Sm-lexodronam combination for refractory and relapsed myeloma. J. Clin. Oncol. 24, S450 (2006).
46. Mahajan A, Anderson PM, Hughes D et al. Multimodality local management of recurrent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatr. Blood Cancer 47, 501 (2006).
47. 153-Sm-lexidronam repetitively administered for castrate metastatic prostate cancer. J. Clin. Oncol. 25 (Suppl. 18), 272 (2007) (Abstract 5152).
48. 153-Sm- lexidronam combination for refractory and relasped multiple myeloma. J. Clin. Oncol. Proc. ASC0 2007.
49. Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:'a randomised Phase II trial. Lancet 357, 336-341 (2001).
50. Menda Y, Bushnell DL, Williams RD et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin. Nucl. Med. 25, 698-700 (2000).
51. Turner JH, Claringbold PG. A Phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetra-methylene phosphonate. Eur. J. Cancer 27, 1084-1086 (1991).
52. Sartor O, Reid RH, Bushnell DL et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109, 637-643 (2007).
53. Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy + radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Review of ifosfamide, glufosfamide, gemcitabine, sapacitabine, samarium, methotrexate, temozolomide, and irinotecan regimens during radiation. Cancer Control (2007) (In Press).
54. Loblaw DA, Wu JS, Kirkbride P et al. Pain flare in patients with bone metastases after palliative radiotherapy - a nested randomized control trial. Support Care Cancer 15, 451-455 (2007).
55. Dafermou A, Colamussi P, Giganti M et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med. 28, 788-798 (2001).
56. Farhanghi M, Holmes RA, Volkert WA et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med. 33, 1451-1458 (1992).
57. Trotti A, Coievas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13, 176-181 (2003).
58. Turner JH, Claringbold PG, Hetherington EL et al. A Phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J. Clin. Oncol. 7, 1926-1931 (1989).
59. Applebaum FR, Sandmaler B, Brown PA. Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Immunoconj. 1, 263-279 (1988).
60. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl. Med. Commun. 13, 321-329 (1992).
61. Bartlett ML, Webb M, Durrant S et al. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur. J. Nucl. Med. Mol, Imaging 29, 1470-1477 (2002).
62. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl. Med. Commun. 23, 1099-1106 (2002).
63. Hogan WJ, Lacy MQ, Wiseman GA et al. Successful treatment of POEMS syndrome with autologous hernatopoietic progenitor cell transplantation. Bone Marrow Transplant. 28, 305-309 (2001).
64. 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19, 118-125 (2005).
65. 153Sm-EDTMP-based preparative regimen. Leukemia 19, 879-880 (2005).
66. Rodriguez V, Erlandson L, Arndt CA et al. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr. Transplant. 9, 122-126 (2005).
67. 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk. Lymphoma 47, 1583-1592 (2006).
68. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 6, 392-400 (2005).
69. Etchebehere EC, Pereira Neto CA, Lima MC et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med. J. 122, 208-212 (2004).
70. Sapienza MT, Ono CR, Guimaraes MI et al. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59, 321-328 (2004).
71. Tap WD, Federman N, Eilber FC. Targeted therapies for soft-tissue sarcomas. Expert Rev. Anticancer Ther. 7, 725-733 (2007).
72. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
73. Issa JP. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13, 1634-1637 (2007).
74. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 7, 297-304 (2007).
75. Watanabe M, Takagi A, Matsuzaki T et al. Knowledge of epigenetic influence for prostate cancer therapy. Curr. Cancer Drug Targets 6, 533-551 (2006).
76. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 12, 27-35 (2005).
77. Lee CT, Bilton SD, Famiglietti RM et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int. J. Radiat. Oncol. Biol. Phys. 63, 362-372 (2005).
78. Anderson P, Salazar-Abshire M. Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives. Curr. Oncol. Rep. 8, 415-422 (2006).
79. Callstrom MR, Atwell TD, Charboneau JW et al. Painful metastases involving bone: percutaneous image-guided cryoablation-prospective trial interim analysis. Radiology 241, 572-580 (2006).
80. Callstrom MR, Charboneau JW, Goetz MP et al. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol. 35, 1-15 (2006).
81. Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo. Clin. Proc. 78, 145-146 (2003).
82. Machak GN, Tkachev SI, Solovyev YN et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin. Proc. 78, 147-155 (2003).
83. Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
84. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
85. Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J. Cancer Res. Clin. Oncol. 131, 60-66 (2005).
86. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys. Med. Biol. 41, 2027-2042 (1996).
87. Lewington VJ. Bone-seeking radionuclides for therapy. J. Nucl. Med. 46(Suppl. 1), S38-S47 (2005).
88. Liepe K, Hliscs R, Kropp J et al. Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother. Radiopharm. 15, 261-265 (2000).
89. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J. Nucl. Med. 44, 953-960 (2003).
90. Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. Am. J. Hosp. Palliat. Care 22, 457-464 (2005).
91. 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, S6250-S6257 (2006).
92. Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 11, 4451-4459 (2005).
93. 89Sr in mice. J. Nucl. Med. 44, 252-259 (2003).